272
Participants
Start Date
September 30, 2003
Primary Completion Date
September 30, 2011
Study Completion Date
September 30, 2011
Peginterferon alfa-2a
Both combination and monotherapy for both genotype 2/3 and genotype non-2/3: 180 μg subcutaneously once weekly.
Ribavirin
For genotype 2/3, 800 mg orally daily, in 2 split doses for 24 weeks. For genotype non-2/3, 1000 mg orally daily for participants weighing \< 75 kg or 1200 mg orally daily for participants weighing ≥ 75 kg, in 2 split doses, for 48 weeks.
Taoyuan District
Herston
Adelaide
New York
New York
Manhasset
Poughkeepsie
Binghamton
Philadelphia
Baltimore
Bergamo
Durham
Statesville
Marietta
Atlanta
Atlanta
Jacksonville
Gainesville
Orlando
Orlando
Wellington
Sarasota
Germantown
Cleveland
Indianapolis
Iowa City
Vandœuvre-lès-Nancy
Plymouth
Thessaloniki
Kansas City
Dallas
Houston
San Antonio
Aurora
Napoli
Boise
Long Beach
San Diego
San Diego
San Francisco
Honolulu
Portland
Bellevue
Seattle
Tacoma
São Paulo
Birmingham
La Jolla
Gainesville
Miami
Framingham
Worcester
Newark
Vineland
Lancaster
Providence
Charlottesville
Ribeirão Preto
Salvador
São Paulo
Warsaw
Ponce
San Juan
San Juan
Santurce
Barcelona
Plymouth
Hoffmann-La Roche
INDUSTRY